Efficacy of antidepressants in child and adolescent depression: a meta-analytic study

J Neural Transm (Vienna). 2006 Mar;113(3):399-415. doi: 10.1007/s00702-005-0340-2. Epub 2005 Aug 3.

Abstract

Objectives: To examine whether antidepressant drugs are superior to placebo in the treatment of juvenile depression.

Method: Extensive literature search was done to retrieve all randomised controlled and all uncontrolled trials describing children and adolescents with a diagnosis of depression who underwent any antidepressant drug treatment. In order to combine results, separate analyses using random effect models were conducted first for controlled and then for both controlled and open studies.

Results: 18 controlled and 23 open trials were submitted to meta-analysis. Tricyclics showed no significant benefit over placebo. Odds ratios for SSRIs were 1.84 (95% CI 1.35-2.50) for controlled and 1.83 (95% CI 1.40-2.40) for controlled and uncontrolled studies suggesting a significant benefit over placebo. Combining all antidepressants also gave confidence interval excluding the value one.

Conclusions: Despite some promising data concerning the use of SSRIs in the treatment of adolescent depression, caution is warranted until the long-term safety of these agents can be demonstrated. Insufficient data are available to judge even the short term merits of these agents in prepubertal children. There is no evidence to support the use of tricyclics in this population.

Publication types

  • Meta-Analysis

MeSH terms

  • Adolescent
  • Age Factors
  • Antidepressive Agents / administration & dosage*
  • Antidepressive Agents / adverse effects
  • Antidepressive Agents, Tricyclic / administration & dosage
  • Antidepressive Agents, Tricyclic / adverse effects
  • Child
  • Clinical Trials as Topic / statistics & numerical data
  • Depressive Disorder / drug therapy*
  • Depressive Disorder / physiopathology
  • Female
  • Humans
  • Male
  • Placebo Effect
  • Selective Serotonin Reuptake Inhibitors / administration & dosage
  • Selective Serotonin Reuptake Inhibitors / adverse effects
  • Treatment Outcome

Substances

  • Antidepressive Agents
  • Antidepressive Agents, Tricyclic
  • Serotonin Uptake Inhibitors